MTOR and hepatocellular carcinoma: The so-called “genomic landscape of HCC” has been rigorously characterized in the work published in 2015 by Schulze and colleagues [60], which identified the major pathways recurrently altered in HCC (in more than 5% of patients), involving mutations in telomerase (60%) [72], WNT/b-catenin (54%), PI3K/AKT/mTOR (51%), TP53/cell cycle (49%), MAP kinase (43%), hepatic differentiation genes (34%), epigenetic regulation (32%), chromatin remodeling (28%), oxidative stress (12%), I16/JAK/STAT (9%), and transforming growth factor-β (TGFβ) (5%) pathways [22,60].